SPHK1 Antibody (YA063)

Sphingosine kinase 1 (SphK1) is a key rate-limiting enzyme in sphingolipid metabolism that phosphorylates sphingosine to generate sphingosine-1-phosphate (S1P)， thereby regulating the sphingolipid rheostat and multiple cellular processes including survival, proliferation, migration, inflammation, and vascular remodeling^[1]. S1P produced by SphK1 functions as a bioactive signaling mediator and activates downstream pathways through S1P receptors, contributing to intracellular signaling and cell-environment communication^[1][2]. Mechanistically, SphK1 is activated by diverse stimuli, including cytokines, growth factors, and MAPK signaling, and translocates from the cytoplasm to the plasma membrane where its catalytic activity is enhanced^[1]. Dysregulated SphK1 expression or activity has been reported in numerous cancers and inflammatory disorders, and elevated SphK1 is frequently associated with tumor progression, drug resistance, and unfavorable clinical outcomes^[2][3][4]. In experimental disease models, SphK1-dependent signaling contributes to inflammatory responses, immune-cell regulation, and cancer cell survival, highlighting its importance in both tumor biology and immune-mediated pathology^[1][3]. Compared with the related isoform SphK2, SphK1 is primarily linked to cell growth and survival signaling, whereas SphK2 exhibits distinct subcellular localization patterns and is more closely associated with apoptosis regulation and epigenetic functions^[1][5]. This functional divergence has stimulated the development of isoform-selective pharmacological tools. For experimental applications, several SphK1 inhibitors, including PF-543, SK1-I, and Safingol, have been widely used to investigate SphK1-dependent signaling and evaluate the therapeutic potential of targeting the SphK1/S1P axis in cancer and inflammatory diseases^[1][3].